Medical Cannabis for Spasticity UK

Cannabis for Muscle Spasticity in the UK: A Clinical Guide

Muscle spasticity represents one of the most debilitating symptoms experienced by patients with multiple sclerosis (MS), spinal cord injury (SCI), and cerebral palsy. Characterized by involuntary muscle contractions, increased muscle tone, and painful rigidity, spasticity significantly impacts mobility, function, and quality of life. In the United Kingdom, medical cannabis has emerged as an evidence-based treatment option, with specific products approved for this indication. This guide explores the clinical evidence, available treatments, and pathways to accessing cannabis-based medicines for spasticity management.

Understanding Muscle Spasticity

Spasticity occurs when damage to the central nervous system disrupts normal motor control pathways. In MS, demyelinating lesions interrupt neural signalling, leading to hyperexcitability of spinal reflexes. SCI causes similar disruption through physical trauma, while cerebral palsy results from developmental abnormalities affecting motor control. The result is increased resistance to passive movement, involuntary muscle contractions, and associated pain. Current first-line treatments including baclofen and tizanidine often produce inadequate symptom relief while causing significant side effects such as sedation and weakness.

Sativex: The Gold Standard Evidence

Sativex (nabiximols) represents the most rigorously studied cannabis-based medicine for spasticity in the UK. This oromucosal spray contains equal proportions of THC (tetrahydrocannabinol) and CBD (cannabidiol) in a 1:1 ratio, delivering approximately 2.7mg of each cannabinoid per spray. The formulation was specifically developed to optimize therapeutic benefit while minimizing intoxicating effects.

Clinical evidence supporting Sativex is substantial. The pivotal randomized controlled trial, known as the CAMS study, enrolled 630 MS patients with resistant spasticity who had failed conventional treatments. Results demonstrated that Sativex produced statistically significant improvements in spasticity scores compared to placebo, with approximately 40% of patients experiencing meaningful clinical benefit. Patients reported improvements not only in muscle tone but also in associated pain, sleep quality, and overall functional ability.

Additional trials in SCI populations have confirmed similar efficacy. The SCIRES-MS trial further validated safety and efficacy data across larger patient cohorts. Follow-up studies extending over several years demonstrate sustained benefit without evidence of tolerance development or escalating dose requirements. Safety monitoring consistently shows that serious adverse events are rare, with most reported effects being mild-to-moderate and manageable through dose adjustment.

The THC:CBD Ratio Advantage

The 1:1 THC:CBD ratio employed in Sativex deserves particular attention. This balanced formulation provides distinct advantages over higher-THC products. CBD acts as a modulator of THC’s effects, reducing psychoactive properties while enhancing therapeutic benefit. CBD possesses independent anti-inflammatory and neuroprotective properties, contributing to spasticity reduction through multiple mechanisms.

CBD increases activation of the 5-HT1A serotonin receptor, which inhibits motor neuron hyperexcitability. It also modulates glycine receptors in the spinal cord, key mediators of motor control. THC provides analgesic effects and direct cannabinoid receptor-mediated modulation of spinal circuits. The combination produces synergistic effects superior to either cannabinoid alone—a phenomenon termed the “entourage effect.” This balanced approach minimizes cognitive impairment while maximizing spasticity relief, making it particularly suitable for patients concerned about intoxication or impaired mental function.

Prescription Access in the UK

Following regulatory approval in 2010, Sativex became available on the NHS under specific criteria. Patients must have documented MS with inadequate response to conventional spasticity treatments such as baclofen or tizanidine. Access typically requires specialist neurology assessment, with prescribing usually initiated in secondary care settings.

The prescription pathway involves several steps. First, patients must be formally evaluated by a neurologist or MS specialist who confirms diagnosis and documents failed conventional therapies. Second, baseline spasticity severity must be measured using standardized scales such as the Modified Ashworth Scale. Third, patients receive detailed counselling regarding expected benefits, potential side effects, driving implications, and legal status. Fourth, a trial period typically establishes optimal dosing and tolerability before long-term prescribing.

Private prescribing options exist through private best UK cannabis clinics, though costs can reach £600-£1000 monthly. Some patients access alternative products including CBD-dominant formulations, though evidence specifically for spasticity is stronger for balanced products like Sativex.

Alternative Products and Considerations

Beyond Sativex, other cannabis-based medicines may be prescribed under specialist supervision. Full-spectrum flower-based products contain variable cannabinoid ratios and may provide therapeutic benefit, though evidence is less robust. CBD-dominant products offer lower intoxication risk but less evidence for spasticity specifically. Some neurologists recommend products with THC:CBD ratios between 1:2 and 1:1, maintaining balanced therapeutic properties while adjusting intoxication based on individual tolerance.

Monitoring and Safety

Successful cannabis-based medicine use requires ongoing specialist monitoring. Patients should expect regular review appointments assessing symptom improvement, side effects, cognitive function, and driving safety. Drug interaction screening is essential, particularly with medications metabolized through CYP3A4 and CYP2C19 pathways. Psychiatric history requires careful evaluation given cannabis interactions with mental health conditions.

Conclusion

Medical cannabis represents an evidence-based option for patients with MS, SCI, and cerebral palsy experiencing resistant spasticity. Sativex, with its balanced 1:1 THC:CBD formulation, offers the strongest clinical evidence and represents a rational therapeutic choice when conventional treatments fail.